摘要
目的:为激励基本药物生产企业积极生产基本药物提供政策建议。方法:以政府可以观测的基本药物生产比例作为考察指标,运用委托代理模型分析政府对企业的弹性补偿机制和最优固定补偿水平。结果与结论:政府应该在不高于社会药品费用节约系数的前提下对企业设定较高的激励强度,同时应该根据激励强度的高低、基本药物与非基本药物的价格差异程度、企业保留收入的高低设定最优的固定补偿水平。
OBJECTIVE:To provide policy recommendations for encouraging the manufacturers to produce essential drugs actively.METHODS:The flexible reimbursement mechanism and the optimal level of fixed reimbursement were analyzed by principal-agent model with the percentage of essential drugs that can be observed as index.RESULTS CONCLUSIONS:A higher incentive intensity should be set by the government on the premise of no exceeding the saving coefficient of social drug cost.The optimal level of fixed reimbursement should be based on the excitation intensity,the price differences between essential drugs and non-essential drugs and reservation revenue of the enterprise.
出处
《中国药房》
CAS
CSCD
2012年第44期4138-4142,共5页
China Pharmacy
基金
中国药科大学医药产业发展研究中心社科基金项目(CPUSJ1106)
江苏省高校哲学社会科学基金项目(2011SJD630018)
关键词
基本药物
生产企业
委托代理理论
激励机制
Essential drug
Manufacturer
Theory of principal-agent
Incentive mechanism